Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual Immunotherapy of Birch Pollen Associated Apple Allergy
NCT01449786Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Mar 2012
- Primary completion
- Feb 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of rMal d 1 in food allergy and birch pollen allergy (3 arms), sponsored by Medical University of Vienna. Primary endpoint: Allergen concentration to induce allergic reactions in the oral cavity as a measure of efficacy (oral provocation test) at 1 year. Started Mar 2012; status: completed.
02
Drugs
rMal d 1
03
Conditions
food allergybirch pollen allergy
Beyond the preview
Go deeper on NCT01449786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01449786.